<p>Oxford is developing a COVID-19 vaccine with&nbsp;Serum Institute of India, and as the trials further, the CEO&nbsp;Adar Poonawalla has claimed that the vaccine will be available till the end of the year.</p>

<p>As per the CEO, the trials of the Covishield, the coronavirus vaccine, are showing promising results and may be available for production by December. However, he also added that the claim is being made on the basis of the data collected in the UK.</p>

<p>"A&nbsp;lot is subject to data from the UK and also a lot depends on the approvals coming through from the Drugs Controller General Of India," Poonawalla told an Indian media house.</p>

<p><a href="https://www.wionews.com/world/first-generation-of-coronavirus-vaccine-likely-to-be-imperfect-says-uk-taskforce-338477"><strong>Also read|&nbsp;First generation of coronavirus vaccine 'likely to be imperfect', says UK taskforce</strong></a></p>

<p>As per the statement, the researchers will apply for emergency authorisation with the&nbsp;Drugs Controller General Of India if the data from the trials show promising results. Whether or not there will be a need to apply for emergency authorisation will not be clear till the last stage.</p>

<p>He took to Twitter to share the "good news", saying "A lot of people were wondering and asking the question, will these early vaccines be effective for the elderly and most vulnerable, here is some preliminary good news."</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">A lot of people were wondering and asking the question, will these early vaccines be effective for the elderly and most vulnerable, here is some preliminary good news. <a href="https://t.co/QEnuifxuiW">https://t.co/QEnuifxuiW</a></p>
— Adar Poonawalla (@adarpoonawalla) <a href="https://twitter.com/adarpoonawalla/status/1320752441730633730?ref_src=twsrc%5Etfw">October 26, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>Findings on blood tests carried out on a subset of older participants echo data released in July that showed the vaccine generated robust immune responses in healthy adults ages 18 to 55, AstraZeneca said Monday.</p>

<p>“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher,” AstraZeneca told an American local media channel. “The results further build the body of evidence for the safety and immunogenicity” of the vaccine candidate</p>

<p>The vaccine being developed by Oxford is one of the front runners in the race of several other vaccines being tested by Russia, China and few of the more first-world countries.</p>


Oxford is developing a COVID-19 vaccine with Serum Institute of India, and as the trials further, the CEO Adar Poonawalla has claimed that the vaccine will be available till the end of the year.

Oxford is developing a COVID-19 vaccine with Serum Institute of India, and as the trials further, the CEO Adar Poonawalla has claimed that the vaccine will be available till the end of the year. As per the CEO, the trials of the Covishield, the coronavirus vaccine, are showing promising results and may be available for production by December. However, he also added that the claim is being made on the basis of the data collected in the UK. "A lot is subject to data from the UK and also a lot depends on the approvals coming through from the Drugs Controller General Of India," Poonawalla told an Indian media house. Also read| First generation of coronavirus vaccine 'likely to be imperfect', says UK taskforce As per the statement, the researchers will apply for emergency authorisation with the Drugs Controller General Of India if the data from the trials show promising results. Whether or not there will be a need to apply for emergency authorisation will not be clear till the last stage. He took to Twitter to share the "good news", saying "A lot of people were wondering and asking the question, will these early vaccines be effective for the elderly and most vulnerable, here is some preliminary good news." A lot of people were wondering and asking the question, will these early vaccines be effective for the elderly and most vulnerable, here is some preliminary good news. https://t.co/QEnuifxuiW — Adar Poonawalla (@adarpoonawalla) October 26, 2020 × Findings on blood tests carried out on a subset of older participants echo data released in July that showed the vaccine generated robust immune responses in healthy adults ages 18 to 55, AstraZeneca said Monday. “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher,” AstraZeneca told an American local media channel. “The results further build the body of evidence for the safety and immunogenicity” of the vaccine candidate The vaccine being developed by Oxford is one of the front runners in the race of several other vaccines being tested by Russia, China and few of the more first-world countries.

Oxford's COVID-19 vaccine will be ready by December: Serum Institute CEO Adar Poonawalla

<p>Drugs Controller General of India (DGCI) has issued a show-cause notice to Serum Institute, the world's third largest vaccine manufacturer over safety issues in COVID-19 vaccine trials. DGCI has asked Serum Institute why trials of Covishield were not stopped in India even when the same vaccine-candidate caused illness in one of the participants of the trials.</p>

<p>Trials of the vaccine in the UK were put on hold after after one of the participants developed an unexplained illness. The vaccine is being developed by AstraZeneca and Oxford Univesrity.</p>

<p>"As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said earlier on Wednesday.</p>

<p><br />
<strong>Also Read: <a href="https://www.wionews.com/india-news/oxford-university-covid-19-vaccine-trials-in-india-to-continue-despite-pause-in-uk-serum-institute-326243">Oxford University Covid-19 vaccine trials in India to continue despite 'pause' in UK: Serum Institute</a></strong><br />
&nbsp;</p>

<p>The company spokesperson also added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently.</p>

<p>Serum Institute, which has been conducting trials of the vaccine in India, said on Wednesday (September 9) that they encountered "no issues".</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing &amp; we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials. <a href="https://t.co/gL7IirfnXy">https://t.co/gL7IirfnXy</a></p>
— ANI (@ANI) <a href="https://twitter.com/ANI/status/1303631201157042176?ref_src=twsrc%5Etfw">September 9, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>&nbsp;</p>

<p>"We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing &amp; we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials," Serum Institute was quoted as saying by ANI.</p>


Drugs Controller General of India (DGCI) has issued a show-cause notice to Serum Institute, the world's third largest vaccine manufacturer over safety issues in COVID-19 vaccine trials.

Drugs Controller General of India (DGCI) has issued a show-cause notice to Serum Institute, the world's third largest vaccine manufacturer over safety issues in COVID-19 vaccine trials. DGCI has asked Serum Institute why trials of Covishield were not stopped in India even when the same vaccine-candidate caused illness in one of the participants of the trials. Trials of the vaccine in the UK were put on hold after after one of the participants developed an unexplained illness. The vaccine is being developed by AstraZeneca and Oxford Univesrity. "As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said earlier on Wednesday. Also Read: Oxford University Covid-19 vaccine trials in India to continue despite 'pause' in UK: Serum Institute The company spokesperson also added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently. Serum Institute, which has been conducting trials of the vaccine in India, said on Wednesday (September 9) that they encountered "no issues". We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing & we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials. https://t.co/gL7IirfnXy — ANI (@ANI) September 9, 2020 × "We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing & we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials," Serum Institute was quoted as saying by ANI.

Why haven't COVID-19 vaccine trials stopped? DCGI asks Serum Institute over safety concerns

<p>Serum Institute, the Pune-based third largest&nbsp;manufacturer of vaccines in the world has said that it will continue with Covid-19 vaccine trials in India. Serum Institute said that they had not faced any issues. Trials of the same vaccine have be paused in UK after one of the patients developed illness.</p>

<p>"We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing &amp; we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials," Serum Institute was quoted as saying by ANI</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing &amp; we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials. <a href="https://t.co/gL7IirfnXy">https://t.co/gL7IirfnXy</a></p>
— ANI (@ANI) <a href="https://twitter.com/ANI/status/1303631201157042176?ref_src=twsrc%5Etfw">September 9, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>&nbsp;</p>

<p>The vaccine, which is known as Covishield in India, is being develped by Oxford University and AstraZeneca.</p>

<p>AstraZeneca, the pharmaceutical giant, "voluntarily paused" clinical trials of the Coronavirus vaccine after a volunteer developed an unexplained illness. AstraZeneca called it a routine action but this pause in the clinical trials made headlines everywhere. The vaccine, being developed by Oxford University and AstraZeneca is considered to be the frotrunner in the race to develop vaccine against coronavirus.</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="http://13.235.153.162/videos/astrazeneca-covid-19-vaccine-study-paused-after-a-participant-fall-ill-in-uk-326226/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>&nbsp;</p>

<p>"As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said earlier on Wednesday.</p>

<p>The company spokesperson also added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently.</p>

<p><strong>Also&nbsp;Read: <a href="https://www.wionews.com/world/astrazeneca-voluntarily-pauses-clinical-trials-for-oxfords-covid-19-vaccine-after-unexplained-illness-326112">AstraZeneca 'voluntarily pauses' clinical trials for Oxford's COVID-19 vaccine after unexplained illness</a></strong><br />
&nbsp;</p>

<p>"We are working to expedite the review of the single event to minimise any potential impact on the trial timeline," the spokesperson said.</p>

<p>The nature and severity of illness or where the patient was not clear immediately.&nbsp;</p>


Serum Institute, the Pune-based third largest manufacturer of vaccines in the world has said that it will continue with Covid-19 vaccine trials in India. Serum Institute said that they had not faced any issues.

Serum Institute, the Pune-based third largest manufacturer of vaccines in the world has said that it will continue with Covid-19 vaccine trials in India. Serum Institute said that they had not faced any issues. Trials of the same vaccine have be paused in UK after one of the patients developed illness. "We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing & we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials," Serum Institute was quoted as saying by ANI We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing & we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials. https://t.co/gL7IirfnXy — ANI (@ANI) September 9, 2020 × The vaccine, which is known as Covishield in India, is being develped by Oxford University and AstraZeneca. AstraZeneca, the pharmaceutical giant, "voluntarily paused" clinical trials of the Coronavirus vaccine after a volunteer developed an unexplained illness. AstraZeneca called it a routine action but this pause in the clinical trials made headlines everywhere. The vaccine, being developed by Oxford University and AstraZeneca is considered to be the frotrunner in the race to develop vaccine against coronavirus. × "As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said earlier on Wednesday. The company spokesperson also added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently. Also Read: AstraZeneca 'voluntarily pauses' clinical trials for Oxford's COVID-19 vaccine after unexplained illness "We are working to expedite the review of the single event to minimise any potential impact on the trial timeline," the spokesperson said. The nature and severity of illness or where the patient was not clear immediately.

Oxford University Covid-19 vaccine trials in India to continue despite 'pause' in UK: Serum Institute

<p>Bangladesh`s Beximco Pharmaceuticals is investing in the Serum Institute of India (SII) to ensure Dhaka gets priority access to COVID-19 vaccines being developed by the Indian drug manufacturer, the company said on Friday.</p>

<p>The deal announced by the Bangladeshi generic drugmaker comes after Dhaka said this month it was ready to hold trials of candidate vaccines being developed by India as both countries seek to curb the spread of the virus.</p>

<p>SII has partnered with AstraZeneca, the Gates Foundation and the Gavi vaccine alliance to produce more than a billion doses of a COVID-19 vaccine for global supply.</p>

<p><a href="https://www.wionews.com/india-news/covid-19-delhi-records-highest-single-day-cases-in-august-death-toll-rises-to-over-4400-323981"><strong>Also read|&nbsp;COVID-19: Delhi records highest single-day cases in August; death toll rises to over 4,400</strong></a></p>

<p>"The investment amount will be treated as an advance and once the vaccine receives regulatory approvals, SII will include Bangladesh among the countries who will be the first to receive an agreed quantity of this vaccine from SII on a priority basis," Beximco said in a statement.</p>

<p>It did not give details about the size of the investment in SII nor how many vaccines Beximco might receive.</p>

<p>"This landmark agreement reflects the deep-rooted desire for collaboration between the two countries and as representatives of the two nations, between us we can go a long way towards helping to mitigate the health crisis caused by the COVID-19 pandemic," the heads of both companies said in the statement.</p>

<p><a href="https://www.wionews.com/india-news/india-has-one-of-lowest-global-covid-19-fatality-rates-029-cases-on-ventilators-harsh-vardhan-323962"><strong>Also read|&nbsp;India has one of lowest global COVID-19 fatality rates, 0.29% cases on ventilators: Harsh Vardhan</strong></a></p>

<p>It said Beximco would be the exclusive supplier in Bangladesh for the vaccine being developed by SII and that the Bangladeshi company would discuss with the government the number of doses it wants. Beximco will also secure additional doses to be distributed to the private pay market in Bangladesh.</p>

<p>The Serum Institute is the world`s largest manufacturer of vaccines by volume. It is holding trials for three potential coronavirus vaccines, including one licensed to AstraZeneca by Oxford University.</p>

<p>Bangladesh has also approved a late-stage trial of a potential coronavirus vaccine developed by China`s Sinovac Biotech Ltd in the hope of being a priority recipient for the jab.</p>

<p>Bangladesh confirmed 47 more deaths and reported 2,211 new cases on Friday, taking the total number of cases in the country to 306,794 with 4,174 deaths.</p>

<p>India reported a record daily jump of 77,266 coronavirus infections on Friday, taking its total number of cases to 3.39 million with 61,529 deaths.</p>


Bangladesh`s Beximco Pharmaceuticals is investing in the Serum Institute of India (SII) to ensure Dhaka gets priority access to COVID-19 vaccines being developed by the Indian drug manufacturer, the company said on Friday.

Bangladesh`s Beximco Pharmaceuticals is investing in the Serum Institute of India (SII) to ensure Dhaka gets priority access to COVID-19 vaccines being developed by the Indian drug manufacturer, the company said on Friday. The deal announced by the Bangladeshi generic drugmaker comes after Dhaka said this month it was ready to hold trials of candidate vaccines being developed by India as both countries seek to curb the spread of the virus. SII has partnered with AstraZeneca, the Gates Foundation and the Gavi vaccine alliance to produce more than a billion doses of a COVID-19 vaccine for global supply. Also read| COVID-19: Delhi records highest single-day cases in August; death toll rises to over 4,400 "The investment amount will be treated as an advance and once the vaccine receives regulatory approvals, SII will include Bangladesh among the countries who will be the first to receive an agreed quantity of this vaccine from SII on a priority basis," Beximco said in a statement. It did not give details about the size of the investment in SII nor how many vaccines Beximco might receive. "This landmark agreement reflects the deep-rooted desire for collaboration between the two countries and as representatives of the two nations, between us we can go a long way towards helping to mitigate the health crisis caused by the COVID-19 pandemic," the heads of both companies said in the statement. Also read| India has one of lowest global COVID-19 fatality rates, 0.29% cases on ventilators: Harsh Vardhan It said Beximco would be the exclusive supplier in Bangladesh for the vaccine being developed by SII and that the Bangladeshi company would discuss with the government the number of doses it wants. Beximco will also secure additional doses to be distributed to the private pay market in Bangladesh. The Serum Institute is the world`s largest manufacturer of vaccines by volume. It is holding trials for three potential coronavirus vaccines, including one licensed to AstraZeneca by Oxford University. Bangladesh has also approved a late-stage trial of a potential coronavirus vaccine developed by China`s Sinovac Biotech Ltd in the hope of being a priority recipient for the jab. Bangladesh confirmed 47 more deaths and reported 2,211 new cases on Friday, taking the total number of cases in the country to 306,794 with 4,174 deaths. India reported a record daily jump of 77,266 coronavirus infections on Friday, taking its total number of cases to 3.39 million with 61,529 deaths.

Bangladesh's Beximco signs COVID-19 vaccine deal with India's Serum Institute

<p>Serum Institute of India said on Friday it would receive $150 million in funding from the Bill &amp; Melinda Gates Foundation and the GAVI vaccines alliance to make 100 million COVID-19 vaccine doses for India and other emerging economies as early as 2021.</p>

<p>The candidate vaccines, including those from AstraZeneca and Novavax, will be priced at $3 per dose and will be made available in 92 countries in GAVI's COVAX Advance Market Commitment (AMC), the company said in a statement.</p>

<p><strong>Also read |&nbsp;<a href="https://www.wionews.com/india-news/indias-covid-19-tally-crosses-20-lakh-with-highest-single-day-spike-of-62538-318766">India's COVID-19 tally crosses 20 lakh with highest single-day spike of 62,538</a></strong></p>

<p>The Gates Foundation will provide the funds to GAVI, which will be used to support Serum Institute.</p>

<p>GAVI, backed by the Gates Foundation, is a public–private global health partnership with the goal of increasing access to immunization in poor countries.</p>

<p>It co-leads COVAX - a scheme designed to guarantee fast and equitable access globally to COVID-19 vaccines - along with the World Health Organization and the Coalition for Epidemic Preparedness Innovations (CEPI).</p>

<p>COVAX aims to deliver 2 billion doses of approved and effective COVID-19 vaccines by the end of 2021.</p>

<p>India reported a record jump in daily coronavirus infections on Friday and became the third country in the world to surpass 2 million cases. It lags only the United States and Brazil in the number of infections.</p>


Serum Institute of India said on Friday it would receive $150 million in funding from the Bill & Melinda Gates Foundation and the GAVI vaccines alliance to make 100 million COVID-19 vaccine doses for India and other emerging economies as early as 2021.

Serum Institute of India said on Friday it would receive $150 million in funding from the Bill & Melinda Gates Foundation and the GAVI vaccines alliance to make 100 million COVID-19 vaccine doses for India and other emerging economies as early as 2021. The candidate vaccines, including those from AstraZeneca and Novavax, will be priced at $3 per dose and will be made available in 92 countries in GAVI's COVAX Advance Market Commitment (AMC), the company said in a statement. Also read | India's COVID-19 tally crosses 20 lakh with highest single-day spike of 62,538 The Gates Foundation will provide the funds to GAVI, which will be used to support Serum Institute. GAVI, backed by the Gates Foundation, is a public–private global health partnership with the goal of increasing access to immunization in poor countries. It co-leads COVAX - a scheme designed to guarantee fast and equitable access globally to COVID-19 vaccines - along with the World Health Organization and the Coalition for Epidemic Preparedness Innovations (CEPI). COVAX aims to deliver 2 billion doses of approved and effective COVID-19 vaccines by the end of 2021. India reported a record jump in daily coronavirus infections on Friday and became the third country in the world to surpass 2 million cases. It lags only the United States and Brazil in the number of infections.

Serum Institute to get $150 million from Gates Foundation for COVID-19 vaccine

serum-institute

Serum Institute, News on Serum Institute, stories on Serum Institute, articles on Serum Institute, Serum Institute stories at Wion, Serum Institute news, Serum Institute latest news

serum institute

Oxford's COVID-19 vaccine will be ready by December: Serum Institute CEO Adar Poonawalla

Why haven't COVID-19 vaccine trials stopped? DCGI asks Serum Institute over safety concerns

Oxford University Covid-19 vaccine trials in India to continue despite 'pause' in UK: Serum Institute

Bangladesh's Beximco signs COVID-19 vaccine deal with India's Serum Institute

Serum Institute to get $150 million from Gates Foundation for COVID-19 vaccine